Stroke Thrombolysis: Save a Minute, Save a Day

Background and Purpose— Stroke thrombolysis is highly time-critical, but data on long-term effects of small reductions in treatment delays have not been available. Our objective was to quantify patient lifetime benefits gained from faster treatment. Methods— Observational prospective data of consecutive stroke patients treated with intravenous thrombolysis in Australian and Finnish centers (1998–2011; n=2258) provided distributions of age, sex, stroke severity, onset-to-treatment times, and 3-month modified Rankin Scale in daily clinical practice. Treatment effects derived from a pooled analysis of thrombolysis trials were used to model the shift in 3-month modified Rankin Scale distributions with reducing treatment delays, from which we derived the expected lifetime and level of long-term disability with faster treatment. Results— Each minute of onset-to-treatment time saved granted on average 1.8 days of extra healthy life (95% prediction interval, 0.9–2.7). Benefit was observed in all groups: each minute provided 0.6 day in old severe (age, 80 years; National Institutes of Health Stroke Scale [NIHSS] score, 20) patients, 0.9 day in old mild (age, 80 years; NIHSS score, 4) patients, 2.7 days in young mild (age, 50 years; NIHSS score, 4) patients, and 3.5 days in young severe (age, 50 years; NIHSS score, 20) patients. Women gained slightly more than men over their longer lifetimes. In the whole cohort, each 15 minute decrease in treatment delay provided an average equivalent of 1 month of additional disability-free life. Conclusions— Realistically achievable small reductions in stroke thrombolysis delays would result in significant and robust average health benefits over patients’ lifetimes. The awareness of concrete importance of speed could promote practice change.

[1]  Jin-Moo Lee,et al.  Reducing Door-to-Needle Times Using Toyota’s Lean Manufacturing Principles and Value Stream Analysis , 2012, Stroke.

[2]  S. Johnston The Economic Case for New Stroke Thrombolytics , 2010, Stroke.

[3]  K. Welch,et al.  Total quality improvement method for reduction of delays between emergency department admission and treatment of acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1997, Archives of neurology.

[4]  Leonid Churilov,et al.  Thrombolysis for acute stroke in Australia: outcomes from the Safe Implementation of Thrombolysis in Stroke registry (2002–2008) , 2010, The Medical journal of Australia.

[5]  V. Demarin,et al.  Factors Influencing In-Hospital Delay in Treatment With Intravenous Thrombolysis , 2012, Stroke.

[6]  S. Fagan,et al.  Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. , 1999, Neurology.

[7]  M. Kaste,et al.  Does Time of Day Or Physician Experience Affect Outcome of Acute Ischemic Stroke Patients Treated with Thrombolysis? a Study from Finland , 2012, International journal of stroke : official journal of the International Stroke Society.

[8]  Jeffrey L Saver,et al.  Quantifying the Value of Stroke Disability Outcomes: WHO Global Burden of Disease Project Disability Weights for Each Level of the Modified Rankin Scale , 2009, Stroke.

[9]  Atte Meretoja,et al.  Reducing in-hospital delay to 20 minutes in stroke thrombolysis , 2012, Neurology.

[10]  M. Kaste,et al.  Ultraearly Thrombolysis in Acute Ischemic Stroke Is Associated With Better Outcome and Lower Mortality , 2010, Stroke.

[11]  M. Wintermark,et al.  Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association , 2013, Stroke.

[12]  Joanna M. Wardlaw,et al.  Cost-Effectiveness of Thrombolysis With Recombinant Tissue Plasminogen Activator for Acute Ischemic Stroke Assessed by a Model Based on UK NHS Costs , 2004, Stroke.

[13]  B. Kissela,et al.  Eligibility for Intravenous Recombinant Tissue-Type Plasminogen Activator Within a Population: The Effect of the European Cooperative Acute Stroke Study (ECASS) III Trial , 2012, Stroke.

[14]  A. Rabinstein,et al.  Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study , 2008 .

[15]  J. Saver,et al.  Years of Disability-Adjusted Life Gained as a Result of Thrombolytic Therapy for Acute Ischemic Stroke , 2010, Stroke.

[16]  M. Kaste,et al.  Off-Label Thrombolysis Is Not Associated With Poor Outcome in Patients With Stroke , 2010, Stroke.

[17]  Alan D. Lopez,et al.  Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010 , 2012, The Lancet.

[18]  Klaus Fassbender,et al.  Diagnosis and treatment of patients with stroke in a mobile stroke unit versus in hospital: a randomised controlled trial , 2012, The Lancet Neurology.

[19]  Maarten G Lansberg,et al.  Cost-Effectiveness of Tissue-Type Plasminogen Activator in the 3- to 4.5-Hour Time Window for Acute Ischemic Stroke , 2011, Stroke.

[20]  J. Mar,et al.  Cost-Effectiveness Analysis of Thrombolytic Treatment for Stroke , 2005, Cerebrovascular Diseases.

[21]  P. Sandercock,et al.  How many Patients might Receive Thrombolytic Therapy in the Light of the ECASS-3 and IST-3 Data? , 2010, International journal of stroke : official journal of the International Stroke Society.

[22]  Joanna Wardlaw,et al.  Stroke treatment with alteplase given 3·0–4·5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial , 2009, The Lancet Neurology.

[23]  Bernadette A. Thomas,et al.  Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010 , 2012, The Lancet.

[24]  M Frankel,et al.  Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke , 1998, Neurology.

[25]  J. Fox-Rushby,et al.  Calculating and presenting disability adjusted life years (DALYs) in cost-effectiveness analysis. , 2001, Health policy and planning.

[26]  Lorenz Breuer,et al.  Avoiding in Hospital Delays and Eliminating the Three-Hour Effect in Thrombolysis for Stroke , 2011, International journal of stroke : official journal of the International Stroke Society.

[27]  Adrian F Hernandez,et al.  Timeliness of Tissue-Type Plasminogen Activator Therapy in Acute Ischemic Stroke: Patient Characteristics, Hospital Factors, and Outcomes Associated With Door-to-Needle Times Within 60 Minutes , 2011, Circulation.

[28]  J. Saver Time Is Brain—Quantified , 2006, Stroke.

[29]  M. Endres,et al.  Prehospital thrombolysis in acute stroke , 2013, Neurology.

[30]  Mette Kjølby,et al.  Cost-Effectiveness of Intravenous Thrombolysis With Alteplase Within a 3-Hour Window After Acute Ischemic Stroke , 2007, Stroke.

[31]  Eric E. Smith,et al.  Improving Door-to-Needle Times in Acute Ischemic Stroke: The Design and Rationale for the American Heart Association/American Stroke Association's Target Stroke Initiative , 2011, Stroke.

[32]  C. Marra,et al.  Cost-Utility analysis of tissue plasminogen activator therapy for acute ischaemic stroke: a Canadian healthcare perspective. , 2001, PharmacoEconomics.

[33]  Werner Hacke,et al.  Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study , 2007, The Lancet.

[34]  Atte Meretoja,et al.  Helsinki model cut stroke thrombolysis delays to 25 minutes in Melbourne in only 4 months , 2013, Neurology.

[35]  Gregory W Albers,et al.  Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials , 2010, The Lancet.

[36]  Adrian F Hernandez,et al.  Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. , 2013, JAMA.

[37]  M. Kaste,et al.  Pre‐ and in‐hospital intersection of stroke care , 2012, Annals of the New York Academy of Sciences.

[38]  T. Saifee,et al.  Prehospital thrombolysis in acute stroke: Results of the PHANTOM-S pilot study , 2013, Neurology.

[39]  Alan D. Lopez,et al.  Age-specific and sex-specific mortality in 187 countries, 1970–2010: a systematic analysis for the Global Burden of Disease Study 2010 , 2012, The Lancet.